Study of atazanavir-induced hyperbilirubinemia among HIV patients on second-line anti-retroviral therapy

• Váldodahkkit: K Ravi (Dahkki), G N Devamsh (Dahkki), K J Umesh (Dahkki), B C Prashant (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wolters Kluwer Medknow Publications, 2020-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction: Ritonavir-boosted atazanavir (ATV/r) is the preferred second-line protease inhibitor option for HIV patients as per the NACO guidelines. Atazanavir is a protease inhibitor with several advantages including once-daily dosing, low pill burden, and favorable effect on lipid profile compar...